西妥昔单抗
杜瓦卢马布
医学
肿瘤科
内科学
临床终点
头颈部鳞状细胞癌
头颈部癌
实体瘤疗效评价标准
银耳霉素
不利影响
临床研究阶段
癌症
免疫疗法
化疗
临床试验
易普利姆玛
彭布罗利珠单抗
结直肠癌
作者
Shuchi Gulati,McKenzie Crist,Muhammed Kashif Riaz,Vinita Takiar,Maria Lehn,Ilaina Monroe,Sarah Palackdharry,Nicky Kurtzweil,Roman Jandarov,Nusrat Harun,Trisha M. Wise‐Draper
标识
DOI:10.1158/1078-0432.ccr-22-3886
摘要
Abstract Purpose: The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and suppression of antitumor immunity. We hypothesized that adding an immune-checkpoint inhibitor (ICI) could overcome this and lead to an enhanced antitumor response. Patients and Methods: A phase II study of cetuximab and durvalumab in metastatic HNSCC was conducted. Eligible patients had measurable disease. Patients who had received both cetuximab and an ICI were excluded. The primary endpoint was objective response rate (ORR) by RECIST 1.1 at 6 months. Results: As of April 2022, 35 patients enrolled, of whom 33 received at least 1 dose of durvalumab and were included in the response analysis. Eleven patients (33%) had received prior platinum-based chemotherapy, 10 an ICI (30%), and 1 patient (3%) cetuximab. ORR was 39% (13/33) with a median duration of response of 8.6 months [95% confidence interval (CI): 6.5–16.8]. Median progression-free and overall survivals were 5.8 months (95% CI: 3.7–14.1) and 9.6 months (95% CI: 4.8–16.3), respectively. There were 16 grade 3 treatment-related adverse events (TRAE) and one grade 4 TRAE, with no treatment-related deaths. Overall and progression-free survival did not correlate with PD-L1 status. NK cell cytotoxic activity was increased by cetuximab and further increased with the addition of durvalumab in responders. Conclusions: The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI